Abstract: Systems and methods are provided for processing and analyzing workout or other fitness data associated with a user. For example, a fitness analysis system may electronically receive workout data indicating performance of a user with respect to each of a number of different workouts completed by the user, where a given workout may include multiple movements. The workout data may be processed and analyzed to determine features or aspects of fitness or health that are relatively strong or weak for the given user by applying one or more rule sets and/or based on comparisons among a variety of the processed data. One or more user interfaces may then be generated providing graphical or other indications of fitness strengths or weaknesses determined by the fitness analysis system.

Abstract: Systems and methods are provided for processing workout or other fitness data associated with a user and generating scores, reports and/or other analysis based on the processed data. For example, a fitness analysis system may electronically receive workout data indicating performance of a user with respect to each of a number of different workouts completed by the user, where a given workout may include multiple movements. A fitness category may be automatically assigned to a given workout by, for example, analyzing attributes of movements included in the workout. A category-based score may then be generated for the user for each of a number of different fitness categories, and an overall fitness score determined based at least in part on the generated category scores.

Abstract: The present invention relates to a melanin concentrating hormone antagonist compound of formula I: or a pharmaceutically acceptable salt thereof, useful for the treamtment useful fog treating Type H diabetes and/or obesity.

Abstract: The present invention relates to a melanin concentrating hormone antagonist compound of Formula I: (I) wherein Ar1, Ar2, Ar3, L1, L2 and Q areas defined, or a pharmaceutically acceptable salt, solvate, enantiomer or mixture of diastereomers thereof useful in the treatment, prevention or amelioration of symptoms associated with obesity and Related Diseases.

Abstract: The present invention relates to a melanin concentrating hormone antagonist compound of formula I: (I); or a pharmaceutically acceptable salt, solvate, enantiomer or prodrug thereof useful in the treatment, prevention or amelioration of symptoms associated with obesity and related diseases.

Abstract: A novel class of tricyclic compounds of the following formula (I) is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock.